Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells

2010 ◽  
Vol 28 (9) ◽  
pp. 965-969 ◽  
Author(s):  
Sai T Reddy ◽  
Xin Ge ◽  
Aleksandr E Miklos ◽  
Randall A Hughes ◽  
Seung Hyun Kang ◽  
...  
Author(s):  
Vladimir Anatolievich Klimov

Monoclonal antibodies are successfully used to treat a number of viral diseases; they are produced by the plasma cells of the human immune system and are the result of a natural humoral response to the ingress of a certain antigen. Antibodies designed to target only one specific protein — in this case, the protein of the virus that causes COVID-19 — are called «monoclonal». Their purpose is to block the COVID-19 virus and prevent its penetration and replication in human cells, and their ultimate focus is on combating infectious manifestations. They are believed to cause fewer undesirable effects than convalescent plasma, which is essentially a complex of polyclonal antibodies and circulating immune complexes. Monoclonal antibodies can be synthesized in the laboratory using the blood serum of patients who have undergone this disease as a starting material. The use of monoclonal antibodies is indicated for patients with a mild and moderate form of the disease at a high risk of progression of the pathological process to a severe degree, which implies the need for hospitalization and a high probability of a fatal outcome.


2019 ◽  
Author(s):  
Etienne Crickx ◽  
Pascal Chappert ◽  
Sandra Weller ◽  
Aurélien Sokal ◽  
Imane Azzaoui ◽  
...  

AbstractImmune thrombocytopenia (ITP) is an autoimmune disease mediated by pathogenic antibodies directed against platelet antigens, including GPIIbIIIa. Taking advantage of spleen samples obtained from ITP patients, we characterized by multiples approaches the onset of disease relapses occurring after an initial complete response to rituximab. Analysis of splenic B cell immunoglobulin heavy chain gene repertoire at bulk level and from single anti-GPIIbIIIa B cells revealed that germinal centers were fueled by B cells originating from the ongoing lymphopoiesis, but also by rituximab-resistant memory B cells, both giving rise to anti-GPIIbIIIa plasma cells. We identified a population of splenic memory B cells that resisted rituximab through acquisition of a unique phenotype and contributed to relapses, providing a new target in B cell mediated autoimmune diseases.


Cancers ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 15 ◽  
Author(s):  
Francesca Bonello ◽  
Roberto Mina ◽  
Mario Boccadoro ◽  
Francesca Gay

Immunotherapy is the latest innovation for the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) entered the clinical practice and are under evaluation in clinical trials. MAbs can target highly selective and specific antigens on the cell surface of MM cells causing cell death (CD38 and CS1), convey specific cytotoxic drugs (antibody-drug conjugates), remove the breaks of the immune system (programmed death 1 (PD-1) and PD-ligand 1/2 (L1/L2) axis), or boost it against myeloma cells (bi-specific mAbs and T cell engagers). Two mAbs have been approved for the treatment of MM: the anti-CD38 daratumumab for newly-diagnosed and relapsed/refractory patients and the anti-CS1 elotuzumab in the relapse setting. These compounds are under investigation in clinical trials to explore their synergy with other anti-MM regimens, both in the front-line and relapse settings. Other antibodies targeting various antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a promising target and several compounds targeting it have been developed. Encouraging results have been reported with antibody drug conjugates (e.g., GSK2857916) and bispecific T cell engagers (BiTEs®), including AMG420, which re-directs T cell-mediated cytotoxicity against MM cells. Here, we present an overview on mAbs currently approved for the treatment of MM and promising compounds under investigation.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4043-4043
Author(s):  
Ping Zhou ◽  
Lakshmanan K Iyer ◽  
Hani Hassoun ◽  
James E. Hoffman ◽  
Heather Landau ◽  
...  

Abstract Abstract 4043 Cyclin D1 (CCND1) overexpression in AL plasma cells (PC) is associated with patient characteristics such as production of free immunoglobulin (Ig) light chains (FLC) without an intact M-protein (that is, without partner Ig heavy chains), increased cardiac biomarkers and shorter survival (Amyloid 2010;17(S1):61a; Blood 2008;111:4700; Haematologica 2009;94:380). The molecular ramifications of CCND1 overexpression within AL PC clones have not been described. To study these associations, we used CD138+ AL PC from 69 untreated AL patients at diagnosis for (1) gene expression profiling (GEP, Affymetrix U133A 2.0) (n=16), (2) qRT-PCR to validate GEP findings (n=53), and (3) clonal IgVL germline donor gene identification (n=69) by established methods (Blood 2008;111:549; Blood 2001;98:714). By GEP, all cases displayed significant overexpression of the appropriate isotypic IgVL constant region gene, confirming the preponderance of clonal AL PC. Five cases were CCND1hi and 11 CCND1lo, and a supervised analysis of CCND1hi vs CCND1lo transcriptomes showed that in CCND1hi PC among the most down-regulated genes were IGHG1, IGHG3 and CCND2 while among the most up-regulated ones (after CCND1) were FAM129A, WARS, SEC63, PDIA6 and SEL1L. By RT-PCR all 53 cases used for qRT-PCR displayed prominent amplification of spliced and unspliced XBP1, confirming PC derivation. By qRT-PCR, median CCND1 expression was 1.51 (range, 0–19.36) with 27 cases above (CCND1hi) and 26 below the median (CCND1lo) with clear-cut quartile differences (25% 0.02, 75% 4.78). We examined PDIA6 and SEL1L expression by qRT-PCR, and found that both correlated with CCND1 expression (PDIA6, P=0.018, r=0.452; SEL1L, P=0.038, r=0.395). In addition, PDIA6 and SEL1L values above and below the CCND1 median differed significantly (P=0.01, P=0.04). The genes up-regulated in CCND1hi cases are involved in endoplasmic reticulum (ER) and protein control processes: WARS in protein production, FAM129A in autophagy, SEC63 in ER protein transport, PDIA6 in catalysis of disulfide bonds and SEL1L in modifying misfolded proteins and channeling them to cytosolic proteasomes. We then identified the clonal IgVL germline donor genes in the CCND1hi (n=32) and CCND1lo (n=37) AL PC clones. We knew that CCND1hi clones displayed biased Ig light chain restriction with 10/12 κ and 22/57 λ cases being CCND1hi (p=0.009, Fisher's exact). Surprisingly, we also identified biased λ family use as only 6/27 λ1 and λ2 cases were CCND1hi compared to 16/30 λ3 and λ6 cases (P=0.03). Overall these results confirm that CCND1hi AL PC clones express significantly higher levels of important ER protein quality control genes than CCND1lo clones, possibly due to CCND1hi AL PC clones adapting to the production of FLC without partner Ig heavy chains. Moreover, CCND1hi AL PC clones display a biased clonal IgVL germline donor gene repertoire, raising questions about the origin of CCND1hi clones since germline gene selection is an early and CCND1 overexpression likely a late event in malignant clonal PC emergence. Disclosures: No relevant conflicts of interest to declare.


mAbs ◽  
2013 ◽  
Vol 6 (1) ◽  
pp. 143-159 ◽  
Author(s):  
Alison M Clargo ◽  
Ashley R Hudson ◽  
Welcome Ndlovu ◽  
Rebecca J Wootton ◽  
Louise A Cremin ◽  
...  

2009 ◽  
Vol 47 (2-3) ◽  
pp. 407-414 ◽  
Author(s):  
John V. Williams ◽  
Jörn-Hendrik Weitkamp ◽  
David L. Blum ◽  
Bonnie J. LaFleur ◽  
James E. Crowe

Sign in / Sign up

Export Citation Format

Share Document